Patent ID: 9192664
Filing Date: 2015-11-24
Classification: A61K,A61P,C07K

Abstract:
1. A method of selecting the dosage of anti-CD22 antibody to be administered to a human patient with a B-cell malignancy comprising: a) exposing B cells from the human patient to a chimeric, humanized or human anti-CD22 antibody in vitro in the presence of cells selected from the group consisting of PBMCs (peripheral blood mononuclear cells), monocytes, NK cells, and granulocytes, b) measuring the depletion of one or more antigens selected from the group consisting of CD19, CD20, CD21, CD22 and CD79b on the surface of said B cells in vitro using a range of concentrations of the antibody, wherein the antigens are depleted by trogocytosis; and c) selecting a dosage of anti-CD22 antibody to be administered to the patient based on the concentrations of antibody effective to deplete the one or more antigens selected from the group consisting of CD19, CD20, CD21, CD22 and CD79b in vitro, wherein the dosage is capable of inducing trogocytosis of the one or more antigens from the patient's B cells.